Answers are grounded in this paper and cite their sources.
Placental dysfunction remains a central yet incompletely resolved driver of adverse maternal-fetal outcomes, in part because the regulatory architecture governing placental development has been difficult to interrogate in space, time, and living systems. Over the past decade, and accelerating sharply in recent years, advances in spatial transcriptomics, single-cell and single-nucleus epigenomics, and plasma cell-free DNA (cfDNA) analysis have begun to close this gap. We conducted a systematic review, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, to synthesize evidence linking spatially resolved placental regulatory epigenomics with non-invasive maternal plasma cell-free epigenomic signatures and clinically relevant pregnancy outcomes. Comprehensive searches of major biomedical databases and registers identified 1,278 records, of which 28 studies met predefined inclusion criteria. The included literature spans early to late gestation and integrates spatial multiomics, chromatin accessibility profiling, DNA methylation analyses, and plasma cfDNA methylomic and fragmentomic approaches. Across studies, placental regulatory states were shown to be highly region-specific, dynamically remodeled across gestation, and tightly coupled to trophoblast lineage decisions and functional maturation. Importantly, multiple lines of evidence demonstrate that these placental regulatory programs are reflected in maternal plasma through cfDNA methylation patterns, nucleosome footprints, and fragment length distributions, enabling early risk stratification for conditions such as preeclampsia and preterm birth. Beyond summarizing existing findings, this review maps a translational continuum from placental regulatory biology to plasma-based biomarkers and emerging clinical decision pathways. Taken together, the evidence supports a conceptual shift toward viewing maternal plasma epigenomic signals as systemic readouts of placental regulatory health, while underscoring unresolved methodological, ethical, and equity- related challenges that must be addressed before widespread clinical implementation.
No takes yet. Share an insight, caveat, or question.
Andonotopo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: